By Cecilia Butini
Bayer AG said Thursday that its prostate cancer drug Xofigo, or radium-223 dichloride, was approved by the Chinese Medical Products Administration.
The drug, which is defined as a Targeted Alpha Therapy, is indicated in the treatment of patients with castration-resistant prostate cancer who also have symptomatic bone metasthases and no known visceral metasthases, the German pharmaceutical and chemical conglomerate said.
Xofigo is already approved in more than 50 countries, including the U.S., the European Union and Japan, Bayer said.
Write to Cecilia Butini at cecilia.butini@wsj.com
